Skip to main content

Leukemia

FDA Approvals, Leukemia, Lymphoma, Conference Highlights ASCO

Rylaze FDA Approved as Part of a Treatment Regimen for Pediatric Leukemia and Lymphoma

Umbralisib plus Ublituximab Combination Superior to Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia

Wayne Kuznar

First-Line Fixed-Duration Ibrutinib plus Venetoclax Therapy Leads to Deep Remissions in Patients with Chronic Lymphocytic Leukemia

Phoebe Starr

Oral Azacitidine Extends Survival in Acute Myeloid Leukemia, Regardless of MRD Status, in Patients in Remission After Chemotherapy

Wayne Kuznar

Asciminib, First-in-Class STAMP Inhibitor, Superior to Bosutinib in Chronic-Phase CML

Phoebe Starr

FDA Approvals, Leukemia, Select Drug Profiles

Oral Onureg First Drug Approved for Adults with AML in Remission

Leukemia, Lymphoma

Long-Term Data Support Use of Acalabrutinib in Treatment-Naïve Patients with Chronic Lymphocytic Leukemia

Chase Doyle

Leukemia, Lymphoma

Axicabtagene Ciloleucel Induces Durable Responses in Advanced Follicular and Marginal-Zone Lymphoma

Wayne Kuznar

Leukemia, Lymphoma

CAR T-Cell Therapy Shows Highly Durable Remissions in CLL and B-Cell Lymphoma

Chase Doyle

Venetoclax plus Intensive Chemotherapy Shows Promising Results in All Patients with Acute Myeloid Leukemia

Chase Doyle

1
2
3
4

Page 1 of 7
Results 1 - 10 of 70